市場調查報告書

葛瑞夫茲病 - 市場洞察,流行病學,市場預測 2028年

Graves' Disease - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 602064
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
葛瑞夫茲病 - 市場洞察,流行病學,市場預測 2028年 Graves' Disease - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)2018年的葛瑞夫茲病罹患數推定為38萬4,538人,全球整體的葛瑞夫茲病市場規模則為3億630萬美元。美國成為最大的葛瑞夫茲病市場。葛瑞夫茲病的認識度提升和潛力開發平台治療藥促進了葛瑞夫茲病市場的成長。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的葛瑞夫茲病市場調查,總括性彙整市場概要,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 主要洞察

第2章 葛瑞夫茲病市場概要

  • 葛瑞夫茲病的市場佔有率(實際成果值)
  • 葛瑞夫茲病的市場佔有率(預測值)

第3章 疾病概要:葛瑞夫茲病

  • 簡介
  • 病因與症狀
  • 臨床症狀
  • 病理生理學
  • 甲狀腺眼症的病理生理學
  • 葛瑞夫茲病的遺傳的基礎
  • 診斷
    • 日本甲狀腺學會的甲狀腺風暴的診斷標準
    • 用於診斷甲狀腺風暴的Burch-Wartofsky點量表
    • 甲狀腺皮膚症的診斷和鑑別
    • 日本甲狀腺學會:葛瑞夫茲病診斷的指南
  • 葛瑞夫茲病的高感度生物標記
  • 危險因素和併發症

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的整體罹患數

第5章 葛瑞夫茲病:各國流行病學

  • 美國
    • 假設和理論的根據
    • 葛瑞夫茲病的整體罹患數
    • 葛瑞夫茲病的罹患數:性別
    • 葛瑞夫茲病的診斷數
    • 葛瑞夫茲病臨床症狀
  • 歐盟5國
    • 德國
      • 假設和理論的根據
      • 葛瑞夫茲病的整體罹患數
      • 葛瑞夫茲病的罹患數:性別
      • 葛瑞夫茲病的診斷數
      • 葛瑞夫茲病臨床症狀
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和理論的根據
    • 葛瑞夫茲病的整體罹患數
    • 葛瑞夫茲病的罹患數:性別
    • 葛瑞夫茲病的診斷數
    • 葛瑞夫茲病臨床症狀

第6章 現行治療

第7章 葛瑞夫茲病的診療指南

  • 甲狀腺功能亢進症及甲狀腺中毒症等的診斷/管理相關美國甲狀腺學會指南(2016年)
  • 甲狀腺功能亢進症管理的歐洲甲狀腺協會指南(2018年)
  • 甲狀腺眼症管理的歐洲甲狀腺協會/歐洲群組指南(2016年)
  • 日本甲狀腺學會及日本內分泌學會的甲狀腺風暴管理指南(2016年)

第8章 未滿足需求

第9章 已上市治療藥

  • 關鍵交叉競爭

第10章 新藥

  • 關鍵交叉競爭
  • CFZ 533:Novartis
    • 醫藥品概要
    • 臨床開發
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介

第11章 市場分析葛瑞夫茲病:主要7個國家

  • 主要調查結果
  • 主要7個國家的市場規模

第12章 各國市場預測

第13章 美國:市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 歐盟5國:市場預測

  • 德國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
  • 義大利的市場規模
  • 英國的市場規模
  • 西班牙的市場規模

第15章 日本:市場預測

  • 日本的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0291

DelveInsight's "Graves' Disease - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Graves' Disease, historical and forecasted epidemiology as well as the Graves' Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graves' Disease market report provides current treatment practices, emerging drugs, Graves' Disease market share of the individual therapies, current and forecasted Graves' Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Graves' Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Graves' Disease Disease Understanding and Treatment Algorithm

The DelveInsight Graves' Disease market report gives a thorough understanding of the Graves' Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Graves' Disease.

Treatment

It covers the details of conventional and current medical therapies available in the Graves' Disease market for the treatment of the condition. It also provides Graves' Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

Graves' Disease Epidemiology

The Graves' Disease epidemiology division provide insights about historical and current Graves' Disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Graves' Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Graves' Disease Epidemiology

The epidemiology segment also provides the Graves' Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Graves' Disease Drug Chapters

Drug chapter segment of the Graves' Disease report encloses the detailed analysis of Graves' Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Graves' Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Graves' Disease treatment.

Graves' Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Graves' Disease treatment.

Graves' Disease Market Outlook

The Graves' Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Graves' Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Graves' Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Graves' Disease market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Graves' Disease market in 7MM.

The United States Market Outlook

This section provides the total Graves' Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Graves' Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Graves' Disease market size and market size by therapies in Japan is also mentioned.

Graves' Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Graves' Disease market or expected to get launched in the market during the study period 2017-2030. The analysis covers Graves' Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Graves' Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Graves' Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Graves' Disease emerging therapies.

Reimbursement Scenario in Graves' Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Graves' Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Graves' Disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Graves' Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Graves' Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Graves' Disease epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Graves' Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Graves' Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Graves' Disease market

Report Highlights

  • In the coming years, Graves' Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Graves' Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Graves' Disease. Launch of emerging therapies will significantly impact the Graves' Disease market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Graves' Disease
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Graves' Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Graves' Disease Pipeline Analysis
  • Graves' Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Graves' Disease Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Graves' Disease Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Graves' Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Graves' Disease market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Graves' Disease total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Graves' Disease market size during the forecast period (2017-2030)?
  • At what CAGR, the Graves' Disease market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Graves' Disease market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Graves' Disease market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Graves' Disease?
  • What is the historical Graves' Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Graves' Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Graves' Disease?
  • Out of all 7MM countries, which country would have the highest prevalent population of Graves' Disease during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Graves' Disease treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Graves' Disease in the USA, Europe, and Japan?
  • What are the Graves' Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Graves' Disease?
  • How many therapies are developed by each company for Graves' Disease treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Graves' Disease treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Graves' Disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Graves' Disease and their status?
  • What are the key designations that have been granted for the emerging therapies for Graves' Disease?
  • What are the global historical and forecasted market of Graves' Disease?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Graves' Disease market
  • To understand the future market competition in the Graves' Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Graves' Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Graves' Disease market
  • To understand the future market competition in the Graves' Disease market

Table of Contents

1. Key Insights

2. Executive Summary of Graves' Disease

3. Competitive Intelligence Analysis for Graves' Disease

4. Graves' Disease: Market Overview at a Glance

  • 4.1. Graves' Disease Total Market Share (%) Distribution in 2017
  • 4.2. Graves' Disease Total Market Share (%) Distribution in 2030

5. Graves' Disease: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Graves' Disease Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Graves' Disease Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Graves' Disease Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Graves' Disease Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Graves' Disease Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Graves' Disease Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Graves' Disease Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Graves' Disease Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Graves' Disease Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Graves' Disease Treatment and Management
  • 8.2. Graves' Disease Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Graves' Disease Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Graves' Disease: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Graves' Disease Market Size in 7MM
  • 13.3. Graves' Disease Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Graves' Disease Total Market Size in the United States
    • 15.1.2. Graves' Disease Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Graves' Disease Total Market Size in Germany
    • 15.3.2. Graves' Disease Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Graves' Disease Total Market Size in France
    • 15.4.2. Graves' Disease Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Graves' Disease Total Market Size in Italy
    • 15.5.2. Graves' Disease Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Graves' Disease Total Market Size in Spain
    • 15.6.2. Graves' Disease Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Graves' Disease Total Market Size in the United Kingdom
    • 15.7.2. Graves' Disease Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Graves' Disease Total Market Size in Japan
    • 15.8.3. Graves' Disease Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Graves' Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Graves' Disease Epidemiology (2017-2030)
  • Table 2 : 7MM Graves' Disease Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Graves' Disease Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Graves' Disease Epidemiology in Germany (2017-2030)
  • Table 6 : Graves' Disease Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Graves' Disease Epidemiology in France (2017-2030)
  • Table 8 : Graves' Disease Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Graves' Disease Epidemiology in Italy (2017-2030)
  • Table 10 : Graves' Disease Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Graves' Disease Epidemiology in Spain (2017-2030)
  • Table 12 : Graves' Disease Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Graves' Disease Epidemiology in the UK (2017-2030)
  • Table 14 : Graves' Disease Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Graves' Disease Epidemiology in Japan (2017-2030)
  • Table 16 : Graves' Disease Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Graves' Disease Epidemiology (2017-2030)
  • Figure 2 : 7MM Graves' Disease Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Graves' Disease Epidemiology in the United States (2017-2030)
  • Figure 4 : Graves' Disease Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Graves' Disease Epidemiology in Germany (2017-2030)
  • Figure 6 : Graves' Disease Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Graves' Disease Epidemiology in France (2017-2030)
  • Figure 8 : Graves' Disease Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Graves' Disease Epidemiology in Italy (2017-2030)
  • Figure 10 : Graves' Disease Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Graves' Disease Epidemiology in Spain (2017-2030)
  • Figure 12 : Graves' Disease Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Graves' Disease Epidemiology in the UK (2017-2030)
  • Figure 14 : Graves' Disease Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Graves' Disease Epidemiology in Japan (2017-2030)
  • Figure 16 : Graves' Disease Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)